Standing Ovation raises $34.2 million to scale precision-fermented dairy proteins
Standing Ovation’s $34.2 million Series B puts precision-fermented casein on a North America-first launch path, backed by Bpifrance, Crédit Mutuel and Danone Ventures.
Capital is still moving into precision-fermented casein because the payoff is not abstract. Standing Ovation has raised $34.2 million in Series B financing to push its dairy protein into commercial use, with North America as the first market and an expansion plan that reaches into Europe and Asia after that. The round is split between $28.5 million in equity and $5.7 million in non-dilutive financing, a mix that points to both commercial conviction and public-sector support for the category.
The sizing matters, but so does the destination. Standing Ovation said the money will primarily accelerate commercialization in North America and support an increase in existing manufacturing capacity. That is the real transition point for precision fermentation: moving from proving that a protein can be made to proving it can be made at a cost, volume, and consistency that food manufacturers will actually build around. The company has said it is targeting cost parity at 2,000 tons of annual production, which puts scale-up risk squarely at the center of the next phase.
Standing Ovation’s first patented product, Advanced Casein™, is the reason investors are still leaning in. The company says the ingredient matches the structure, amino-acid sequence, and coagulation ability of casein from cow, goat, or sheep milk, but is made without livestock. That functional profile is exactly what plant proteins still struggle to deliver in cheese, yogurt, and high-protein nutrition products, where melt, stretch, emulsification, and flavor retention matter as much as protein percentage.
The financing also underscores how far the company has moved beyond pure technical promise. Bpifrance’s Ecotechnologies 2 fund and Crédit Mutuel Innovation co-led the equity round, while returning backers included Astanor, Bel Group, Seventure Partners, GoodStartup and Big Idea Ventures. Danone Ventures joined alongside Angelor, Newtree and Noshaq. That mix of incumbent dairy names, venture investors and state-backed capital signals a category that is no longer being treated like a speculative lab project. It is being financed like an ingredient business with a path to shelf-ready products.
The strategic logic is easy to see. Standing Ovation was founded in 2020, had already raised a €12 million Series A in 2022 and a €3.75 million extension in 2024, and had built an exclusive partnership with Bel Group for alternative cheese applications after Bel took an equity stake in the company in 2022. Standing Ovation also says its technology can use acid whey and whey permeates as feedstock, turning dairy side streams into a circular input stream instead of relying only on dextrose. With eight patent families around the platform, the company is betting that process know-how, not just the protein itself, will define the moat.
Sources:
Know something we missed? Have a correction or additional information?
Submit a Tip
